[HTML][HTML] Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
RM Krauss, K Wojnooski, J Orr, JC Geaney… - Journal of lipid …, 2012 - ASBMB
We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib
(ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein composition
in 30 healthy individuals. Participants (n= 30) were randomized to ANA 20 mg/day, 150
mg/day, or placebo for 2 weeks. Changes in concentration of lipoprotein subfractions were
assessed using ion mobility, and compositional analyses were performed on fractions
separated by density gradient ultracentrifugation. ANA 150 mg/day versus placebo resulted …
(ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein composition
in 30 healthy individuals. Participants (n= 30) were randomized to ANA 20 mg/day, 150
mg/day, or placebo for 2 weeks. Changes in concentration of lipoprotein subfractions were
assessed using ion mobility, and compositional analyses were performed on fractions
separated by density gradient ultracentrifugation. ANA 150 mg/day versus placebo resulted …